Alpha Cognition (ACOG)
Markets an oral Alzheimer’s treatment while developing related neurodegeneration programs.
Something off on this page? Send us feedback.
Sells ZUNVEYL, an oral treatment for mild-to-moderate Alzheimer’s dementia, through a long-term-care-focused commercial effort. A related pre-clinical pipeline spans ZUNVEYL formulations and other neurodegeneration programs; the business has one commercial product.
ZUNVEYL is an oral benzgalantamine treatment for mild-to-moderate Alzheimer’s dementia. Commercial sales efforts focus on long-term-care customers. It is the company’s one commercial product.
The related neurodegeneration pipeline includes ZUNVEYL combinations with memantine and sublingual or intranasal formulations. ALPHA-0602, ALPHA-0702, and ALPHA-0802 are also at the pre-clinical stage. Manufacturing is outsourced to specialized organizations in Taiwan and the United States for active pharmaceutical ingredient, oral-tablet, and nasal-spray formulations.
The commercial model depends on adoption and reimbursement in long-term care, third-party manufacturing and distribution, continuing safety and regulatory oversight, intellectual-property protection, and capital for commercialization plans.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $41.4M · Total debt $0 · Total assets $64.5M · Shareholders' equity $53.0M
- Revenue
- $6.1M
- Operating income
- −$7.8M
- Net income
- −$8.8M
No dividends on record.
| Institutions | 48.16% | 10.49M shares | |
|---|---|---|---|
| 26 holders · as of Jun 30, 2026 | |||
| Insiders | 5.47% | 1.19M shares | |
| 10 holders · as of Aug 24, 2026 | |||
| Other | 46.37% | 10.10M shares | |
| remainder | |||
21.78M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (21.78M in the company's Sep 23, 2026 report, 15.53M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Opaleye Management Inc.Institution | 13.30% | 2.90M | as of Jun 30, 2026 |
Solas Capital Management, LLCInstitution | 8.84% | 1.92M | as of Jun 30, 2026 |
Awm Investment Company, Inc.Institution | 7.68% | 1.67M | as of Jun 30, 2026 |
Cable Car Capital LLCInstitution | 6.35% | 1.38M | as of Jun 30, 2026 |
Funicular Funds, LPInstitution | 5.12% | 1.11M | filed Feb 19, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Opaleye Management Inc. | 10 percent owner | +80,170 | $8.51 |
| Sep 15, 2026 | Opaleye Management Inc. | 10 percent owner | +3,375 | $8.54 |
| Sep 14, 2026 | Opaleye Management Inc. | 10 percent owner | +40,373 | $8.70 |
| Aug 21, 2026 | Robert James Wills | director | +10,000 | $9.62 |
| Jul 31, 2026 | Opaleye Management Inc. | 10 percent owner | +2,900 | $7.92 |
